Otros idiomas Santen Pharmaceutical Co., Ltd.

Acciones

4536

JP3336000009

Mercado cerrado - Japan Exchange Otros sitios de cotización 08:00:00 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1.529 ^JPY	+0,39 %		+1,09 %	+8,83 %

26/03	Santen Pharmaceutical cancelará 12 millones de acciones propias	MT
25/03	Santen anuncia el cambio de Akira Kurokawa de Director Representante del Consejo a Presidente, con efecto a partir del 1 de abril de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Santen Pharmaceutical : and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL	17/04
Santen Pharmaceutical : Positioned for Further Growth in China Following Completion of Vision Park	16/04
Santen Pharmaceutical : obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis	26/03
Santen Pharmaceutical to Cancel 12 Million Treasury Shares	26/03
Santen Pharmaceutical : Announces Change of Representative Director of the Board	25/03
Santen Pharmaceutical : Announces Cancellation of Treasury Shares	25/03
Santen Pharmaceutical : Announces Completion of Share Buyback	25/03
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	25/03
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	25/03
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.	22/03
Santen Pharmaceutical : Announces Status of Share Buyback	01/03
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months	09/02
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	08/02
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen	08/01
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	05/01
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares	04/12
Santen Pharmaceutical : Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension	17/11
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast	08/11
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	07/11
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	07/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Santen Pharmaceutical Co., Ltd.

Acciones

4536

JP3336000009

Otros idiomas

Filtros